Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Endocrinological Investigation
Published in: Journal of Endocrinological Investigation 5/2008

01-05-2008 | Original Articles

Sustainability of a well-monitored salt iodization program in Iran: Marked reduction in goiter prevalence and eventual normalization of urinary iodine concentrations without alteration in iodine content of salt

Authors: F. Azizi, MD, L. Mehran, R. Sheikholeslam, A. Ordookhani, M. Naghavi, M. Hedayati, M. Padyab, P. Mirmiran

Published in: Journal of Endocrinological Investigation | Issue 5/2008

Login to get access
Metadata
Title
Sustainability of a well-monitored salt iodization program in Iran: Marked reduction in goiter prevalence and eventual normalization of urinary iodine concentrations without alteration in iodine content of salt
Authors
F. Azizi, MD
L. Mehran
R. Sheikholeslam
A. Ordookhani
M. Naghavi
M. Hedayati
M. Padyab
P. Mirmiran
Publication date
01-05-2008
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 5/2008
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/BF03346386

Other articles of this Issue 5/2008

Journal of Endocrinological Investigation 5/2008 Go to the issue

Original Articles

Diagnosis and management of hyperprolactinemia: Results of a Brazilian multicenter study with 1234 patients

Case Report

The many faces of pheochromocytoma

Rapid Communication

Soluble adhesion molecules levels in patients with Cushing’s syndrome before and after cure

Opinion

Lessons from second- and third-generation parathyroid hormone assays in primary hyperparathyroidism

Review Article

Pharmacy and pharmacology of biosimilars

Original Articles

Biochemical markers for cardiovascular risk following treatment in endogenous Cushing’s syndrome
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits